Author

Amanda J. Compadre

Barnes-Jewish HospitalORCID 0000-0003-3182-1170Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:imaging· 1

Frequent Co-Authors

Elena LomonosovaiD· 2 shared Mary Margaret MulleniD· 2 shared Priyanka VermaiD· 2 shared Andrea R. HagemanniD· 1 shared Angela M. SchabiD· 1 shared Ann E. WaltsiD· 1 shared Beth Y. KarlaniD· 1 shared Brooke E. SandersiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elena LomonosovaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 4, 2026

Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers

Lindsey N Aubuchon, Deanna H. Wong, Natasha Ramakrishnan…·Priyanka Verma

This study shows that targeting ALC1 can enhance PARP inhibitor effectiveness in ovarian cancers, particularly in HRD and CCNE1-amplified tumors, with minimal toxicity.

DOI 10.64898/2025.12.04.692458

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedMay 20, 2025

Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer

Angela M. Schab, Amanda J. Compadre, Rikki Drexler…·Mary Margaret Mullen

This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.

11 citationstop 5%

humanimaging

𝕏 PostBluesky